English
Polski
Español
українська
Risk of cancer associated with biologic agents
What do we know about the risk of cancer associated with biologic therapy?
2020-10-09
What do we know about the risk of cancer associated with biologic therapy?
There has been a growing number of cases of new-onset rheumatoid arthritis in older patients. What are the clues to suspect that joint pain may not be caused by osteoarthritis?
How can we differentiate between a flare of systemic lupus erythematosus (SLE) and an infection?
Are there any laboratory biomarkers or other tools that can distinguish immune-mediated rheumatic diseases from other disorders and from possible complications, such as infections?
What conditions have to be excluded in the diagnostic workup of immune-mediated rheumatic diseases?
What is the difference between diagnostic and classification criteria of rheumatic diseases? What should we be aware of when using classification criteria in clinical practice?
Which common and rare adverse effects of biologic therapy should we consider during follow-up?
What has changed in the classification criteria of idiopathic inflammatory myopathies? What subgroups of patients can be distinguished and what are the differences between them?
How can we classify immune-mediated rheumatic diseases? Why is it particularly important to diagnose and treat them early?
What clinical features and laboratory test results suggest idiopathic inflammatory myopathy?
